Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +35

Is This Number The Biggest Risk To Intuitive Surgical Stock?

Guidance lowered Price movement AI-generated analysis

πŸ“‰ Intuitive Surgical plans to reduce da Vinci instrument pricing by 3% to 5% once fully implemented, starting with a billing-code policy change in China.

πŸš€ The company expects procedural volume growth to exceed the price cuts, narrowing the gap between procedure count and revenue per unit.

πŸ’° Management raised its 2026 adjusted gross margin guidance to 68.7%–69.3%, driven by lower product costs and a shift toward da Vinci 5 systems.

πŸ‡ΊπŸ‡Έ U.S. demand remains a key uncertainty, with procedures growing at 10% in Q3 2026 versus 20% growth outside the U.S.

πŸ“ˆ SP procedures surged 55% in fiscal Q3 2026 as da Vinci 5 and Ion systems become larger shares of the business mix.

⚠️ The stock trades at a premium 51x earnings, having underperformed the S&P 500 during recent market shocks like inflation and tariff events.

πŸ“… Management will provide updated operating expense guidance and long-term opportunity estimates in the January 2027 earnings report.

Bullish Signals
  • Intuitive Surgical raised its 2026 adjusted gross margin guidance to a range of 68.7% to 69.3%, driven by lower product costs that boosted margins in fiscal Q3 2026.
  • SP procedures grew 55% in fiscal Q3 2026, indicating strong adoption of newer da Vinci 5 and SP systems which are expected to add to revenue per procedure.
  • Instrument and accessory sales grew 18% in the quarter, outpacing the 15% growth in total procedures, demonstrating strong demand for consumables.
Risk Factors
  • Management expects pricing changes and a specific cut in China to lower da Vinci instrument revenue per procedure by approximately 3% to 5% once fully implemented.
  • U.S. da Vinci procedures grew only 10% in fiscal Q3 2026, significantly trailing the 20% growth seen outside the U.S., raising concerns about domestic demand saturation or regulatory headwinds.
Full Analysis
Intuitive Surgical (ISRG) faces a potential headwind as management plans to reduce pricing for da Vinci instruments and accessories, starting with a significant policy change in China later this year. The company expects these adjustments to lower revenue per procedure by approximately 3% to 5% once fully implemented across all markets. This strategic move aims to address customer value regarding reliability and economics, particularly in high-volume operations like hernia repair, while rolling out longer-life instruments country by country from the first half of 2027. Despite the anticipated price cuts, Intuitive Surgical believes that procedural volume growth will more than offset the revenue impact. Management narrowed its 2026 forecast for da Vinci procedure growth to a range of 14% to 15%, driven by strong international expansion and a shift toward newer systems like da Vinci 5 and SP. Consequently, the company raised its adjusted gross margin guidance for 2026 to between 68.7% and 69.3%, citing lower product costs that helped lift margins in fiscal Q3 2026. Key risks remain centered on U.S. demand dynamics and valuation concerns. While international procedures grew at 20% compared to a 10% increase in the U.S., Intuitive is monitoring challenges related to ACA enrollment and Medicaid eligibility changes. Investors are also weighing the stock's high valuation, trading at 51 times earnings, against its recent performance in market sell-offs, with the upcoming January 2027 earnings report expected to provide critical updates on operating expenses and long-term surgical opportunities.